Fig. 7: O-MRDE/Mn against tumor heterogeneity and synergistic immunotherapeutic effect of M25-MRDE/Mn + CXCL10@Gel plus αPD-1. | Nature Communications

Fig. 7: O-MRDE/Mn against tumor heterogeneity and synergistic immunotherapeutic effect of M25-MRDE/Mn + CXCL10@Gel plus αPD-1.

From: Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment

Fig. 7

a H&E staining images of tumor tissue. b Percentage of mature DCs (CD80+CD86+) in tumor. c Levels of CD8+ T cells (CD3+CD8+). d–f Levels of CD4+ T cells (d), CD8+ T cells (e), and Tregs (f) in tumors. g Schematics of the experimental design for the Synergistic immunotherapy effects of M25-MRDE/Mn+CXCL10@Gel plus αPD-1. h Tumor growth profiles of mice. i Tumor inhibition rate of mice during treatment. j Mice survival rate. k, l levels of NK cells (CD3-CD49b+) (k) and CRT (l) after different treatments. m Levels of mature DCs (CD80+CD86+) in tumors. n, o Levels of IFN-γ+ T cells (CD8+IFN-γ+) (n), and GrB+ T cells (CD8+GrB+) (o). p Levels of Tregs (Foxp3+CD4+) in tumors. q Representative images of lung metastases. r Quantitative analysis of lung metastases. Data were mean ± SD (n = 6 mice per group). The significance between each of the multiple groups in (b–f, i, k–p, and r) was calculated using one-way ANOVA. The significance in (h) was calculated using two-way ANOVA. The significance in (j) between G1 and G2-G6 was calculated using Kaplan-Meier survival analysis. Source data are provided as a Source Data file.

Back to article page